Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

4.905 -0.265 (-5.13%)
Streaming Delayed Price Updated: 2:40 PM EDT, Jun 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 29,367,760
Open 4.955
Bid (Size) 4.900 (156)
Ask (Size) 4.910 (87)
Prev. Close 5.170
Today's Range 4.880 - 5.150
52wk Range 3.790 - 12.36
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Recursion Pharmaceuticals Was Bouncing Higher on Tuesday
Via The Motley Fool
Recursion Pharmaceuticals Stock Is Up 10% Today: What's Happening?
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading higher and trending. The company on Tuesday announced a reduction in personnel and infrastructure aimed at extending its cash runway. 
Via Benzinga

Performance

YTD
-32.0%
-32.0%
1 Month
+8.8%
+8.8%
3 Month
-17.4%
-17.4%
6 Month
-29.7%
-29.7%
1 Year
-47.3%
-47.3%

More News

Read More
Insmed, Tesla, Casey's General Stores And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Recursion Pharmaceuticals Stock Surges After Company Lays Off 20% Workforce: Retail Predicts ‘Blue Skies’ Ahead
Via Stocktwits
Topics Artificial Intelligence Workforce
Exposures Artificial Intelligence Layoff
Earnings Scheduled For May 5, 2025
Via Benzinga
Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio?
Via Benzinga
Recursion Pharmaceuticals Stock Surges On Breakthrough AI Model Launch With MIT
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
3 Monster Stocks to Hold for the Next 10 Years
Via The Motley Fool
Topics Energy
Exposures Electricity Generation
8 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
These Are the Only 6 Stock Stocks in NVIDIA's 13F Portfolio
Via MarketBeat
Topics Artificial Intelligence Earnings
Exposures Artificial Intelligence Financial
Should You Buy This Beaten-Down Artificial Intelligence (AI) Stock on the Dip?
Via The Motley Fool
Topics Animal Testing Artificial Intelligence
Exposures Animal Testing Artificial Intelligence
2 Top Artificial Intelligence (AI) Stocks to Buy Right Now
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Recursion Pharmaceuticals Stock Plummeted 24% This Week
Via The Motley Fool
Topics Artificial Intelligence Government Stocks
Exposures Artificial Intelligence Political US Equities
Why Recursion Pharmaceuticals Stock Is Plummeting Today
Via The Motley Fool
Topics Artificial Intelligence Government Stocks
Exposures Artificial Intelligence Political US Equities
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
Why Recursion Pharmaceuticals Stock Was Getting Mashed on Monday
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Recursion Reports First Quarter 2025 Financial Results and Provides Business Update
From Recursion Pharmaceuticals
Via GlobeNewswire
Retail Traders Bearish On Recursion Pharma Ahead of Q1 Results Despite Positive Tupelo Trial Data
Via Stocktwits
Topics Earnings
Exposures Financial
Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
How Do Investors Really Feel About Recursion Pharmaceuticals?
Via Benzinga
Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth
From FN Media Group LLC
Via GlobeNewswire
Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th
From Recursion Pharmaceuticals
Via GlobeNewswire

Frequently Asked Questions

Is Recursion Pharmaceuticals, Inc. - Class A Common Stock publicly traded?
Yes, Recursion Pharmaceuticals, Inc. - Class A Common Stock is publicly traded.
What exchange does Recursion Pharmaceuticals, Inc. - Class A Common Stock trade on?
Recursion Pharmaceuticals, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock is RXRX on the Nasdaq Stock Market
What is the current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock is 4.905
When was Recursion Pharmaceuticals, Inc. - Class A Common Stock last traded?
The last trade of Recursion Pharmaceuticals, Inc. - Class A Common Stock was at 06/13/25 02:40 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.